(ANAB) – Management Comments
-
Anaptysbio (ANAB) Announces Portfolio Update
-
Anaptysbio (ANAB) Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe GPP
-
-
-
-
-
-
-
-
-
Back to ANAB Stock Lookup